Ventricular Tachycardia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Ventricular Tachycardia - Pipeline Review, H2 2018’, provides an overview of the Ventricular Tachycardia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia

- The report reviews pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ventricular Tachycardia therapeutics and enlists all their major and minor projects

- The report assesses Ventricular Tachycardia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ventricular Tachycardia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ventricular Tachycardia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Audentes Therapeutics Inc

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Audentes Therapeutics Inc

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventricular Tachycardia – Overview

Ventricular Tachycardia – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventricular Tachycardia – Overview

Ventricular Tachycardia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ventricular Tachycardia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventricular Tachycardia – Companies Involved in Therapeutics Development

Audentes Therapeutics Inc

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Ventricular Tachycardia – Drug Profiles

AT-307 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budiodarone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etripamil – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flecainide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBI-3000 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landiolol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Tachycardia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ventricular Tachycardia – Dormant Projects

Ventricular Tachycardia – Discontinued Products

Ventricular Tachycardia – Product Development Milestones

Featured News & Press Releases

Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the phase 3 NODE-301 clinical trial evaluating Etripamil for termination of paroxysmal supraventricular tachycardia (PSVT) episodes

May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer

Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias

Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients

Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Ventricular Tachycardia, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development ...

List of Tables

Number of Products under Development for Ventricular Tachycardia, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ventricular Tachycardia – Pipeline by Audentes Therapeutics Inc, H2 2018

Ventricular Tachycardia – Pipeline by Gilead Sciences Inc, H2 2018

Ventricular Tachycardia – Pipeline by HUYA Bioscience International LLC, H2 2018

Ventricular Tachycardia – Pipeline by InCarda Therapeutics Inc, H2 2018

Ventricular Tachycardia – Pipeline by Milestone Pharmaceuticals Inc, H2 2018

Ventricular Tachycardia – Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Ventricular Tachycardia – Dormant Projects, H2 2018

Ventricular Tachycardia – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Ventricular Tachycardia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Ventricular Tachycardia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports